1. Article | 2020.06.16

   Antibody profiling in recovering patients and development of a serological test for an epidemiological survey in individuals exposed to SARS-CoV-2

   Aim: to develop a test that can be used to carry out an initial survey on the prevalence of antibodies in individuals exposed to the SARS-CoV-2 coronavirus. The aim is to obtain a specific serological test that can be used for high-throughput testing for Covid-19 infection.

2. Article | 2020.06.22

   Protocol for assessment of potential risk factors for 2019-novel coronavirus (2019-nCoV) infection among health care workers in a health care setting

   Aim: Worldwide, the health care workers play an essential role in the clinical management of Covid-19 patients, but in Africa they are also at risk of infection given the level of control measures in hospital wards. This study aims to obtain an early understanding of key epidemiological characteristics in the risk of transmission in healthcare workers in different African countries of the...

3. Article | 2020.06.22

   Evaluation of SARS-CoV-2 infection spread in various populations groups in Cameroon

   Aim: The high case fatality ratio of Covid-19 compared to the flu is a global preoccupation. It could be related to non-reporting of mild and asymptomatic infection whose role in transmission is not completely clear if not diagnosed. It is therefore of paramount importance to quickly evaluate the true extent of the infection of SARS-CoV-2. We planned it in different population groups (close...

4. Article | 2020.06.22

   Neurological implications of SARS-COV-2 infection – a transversal study

   Aim: The infection of the nasal mucosa and the lungs by CoV-2 may spread to the CNS, including the brainstem, thereby playing a potential key role in the severe respiratory distress observed in COVID-19. Although several clinical observations support this hypothesis, the knowledge in this field is very limited. To fill this gap, we will investigate CoV-2 neuroinvasion in humans, animal...

5. Article | 2020.07.07

   Modeling human SARS-CoV-2 infection in mice with human lung xenografts

   To date there is no specific therapeutic treatment or vaccine for COVID-19 caused by the SARS-CoV-2 virus and relevant animal models that mimic human COVID-19 pathologies are lacking. We will generate two novel humanized mouse models: HuLung mice (human lung) and HIS-HuLung mice (and human immune system and human lung). Infection of HuLung and HIS-HuLung mice with SARS-CoV-2 will provide an in...

6. Article | 2020.07.07

   Neurological implications of SARS-COV-2 infection – a transversal study

   Aim: The infection of the nasal mucosa and the lungs by CoV-2 may spread to the CNS, including the brainstem, thereby playing a potential key role in the severe respiratory distress observed in COVID-19. Although several clinical observations support this hypothesis, the knowledge in this field is very limited. To fill this gap, we will investigate CoV-2 neuroinvasion in humans, animal models,...

7. Article | 2020.06.16

   Household transmission investigation study for SARS in overseas territories

   Aim: EPI-COVID-19, a research project in epidemiology to study intra-household transmission around cases of Covid-19 confirmed in French Guiana.The EPI-COVID study, covering 250 households (150 in French Guiana, 50 in Guadeloupe and 50 in New Caledonia), should make it possible to investigate the secondary infection rate, the speed of spread of the virus, the proportion of asymptomatic cases...

8. Report | 2022.07.08

   A historic fight against emerging infectious diseases

   Emerging infectious diseases result from contact between microbes and animals, with humans the most parasitized animal species. From the plague in Asia in 1894 to the current COVID-19 crisis, scientists at the Institut Pasteur have long leveraged their expertise and talent to further knowledge creation and benefit humankind.

9. News | 2022.04.14

   Monoclonal antibody SPK001: potent and broad neutralization activity across all SARS-CoV-2 variants of concern

   SPK001, the monoclonal antibody developed by SpikImm, a biotech company founded by the Institut Pasteur and Truffle Capital, has demonstrated a potent and broad neutralization activity across all SARS-CoV-2 variants of concern, including omicron (BA.1 and BA.2). Originally developed in the Humoral Immunology lab headed by Dr Hugo Mouquet at the Institut Pasteur (joint research unit Inserm),...

10. Document de presse | 2021.08.19

    Immune checkpoint inhibitors improve cellular immunity against SARS-CoV-2

    Researchers and doctors from the AP-HP, the Institut Pasteur, the University of Paris and the Sorbonne University, have carried out work on the effect of immune checkpoint inhibitors (anti-PD1 and anti-CTLA4) on cellular immunity against SARS-CoV-2. This work, the results of which suggest that these treatments are not deleterious during infection with COVID-19 and, on the contrary, seem to...

Pages